{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:32:44Z","timestamp":1768001564300,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1124\/jpet.120.000179","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T13:25:12Z","timestamp":1601645112000},"page":"488-497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis"],"prefix":"10.1016","volume":"375","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-0711","authenticated-orcid":false,"given":"Keito","family":"Hoshitsuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manda J.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry W.","family":"Moreland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian A.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.000179_bib1","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1124\/jpet.120.000179_bib2","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1124\/jpet.120.000179_bib3","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.120.000179_bib4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2009.112847","article-title":"Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study","volume":"69","author":"Bartelds","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.120.000179_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fimmu.2015.00152","article-title":"Immunogenicity of anti-TNF-\u03b1 biotherapies: I. Individualized medicine based on immunopharmacological evidence","volume":"6","author":"Bendtzen","year":"2015","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.120.000179_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fimmu.2015.00109","article-title":"Immunogenicity of anti-TNF-\u03b1 biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection","volume":"6","author":"Bendtzen","year":"2015","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.120.000179_bib7","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.4049\/jimmunol.181.5.3183","article-title":"Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs","volume":"181","author":"Brezski","year":"2008","journal-title":"J Immunol"},{"key":"10.1124\/jpet.120.000179_bib8","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1136\/annrheumdis-2013-203893","article-title":"Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis","volume":"74","author":"Chen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.120.000179_bib9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00002281-200405000-00013","article-title":"Rheumatoid factor revisited","volume":"16","author":"D\u00f6rner","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1124\/jpet.120.000179_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","article-title":"Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases","volume":"38","author":"Emi Aikawa","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1124\/jpet.120.000179_bib11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4049\/jimmunol.1601096","article-title":"Anti-hinge antibodies recognize IgG subclass- and protease-restricted neoepitopes","volume":"198","author":"Falkenburg","year":"2017","journal-title":"J Immunol"},{"key":"10.1124\/jpet.120.000179_bib12","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.120.000179_bib13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/cei.13112","article-title":"Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab","volume":"192","author":"Gorovits","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1124\/jpet.120.000179_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jim.2011.07.019","article-title":"Differential effect of drug interference in immunogenicity assays","volume":"372","author":"Hart","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1124\/jpet.120.000179_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1124\/jpet.120.000179_bib16","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/art.39169","article-title":"Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis [published correction appears in Arthritis Rheumatol (2015) 67:3096]","volume":"67","author":"Jani","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1124\/jpet.120.000179_bib17","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.120.000179_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/ar3147","article-title":"The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review","volume":"12","author":"Krieckaert","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1124\/jpet.120.000179_bib19","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.120.000179_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s41927-019-0090-7","article-title":"A systematic review of guidelines for managing rheumatoid arthritis","volume":"3","author":"Mian","year":"2019","journal-title":"BMC Rheumatol"},{"key":"10.1124\/jpet.120.000179_bib21","first-page":"CD005113","article-title":"Adalimumab for treating rheumatoid arthritis","author":"Navarro-Sarabia","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/jpet.120.000179_bib22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12026-016-8824-8","article-title":"Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits","volume":"65","author":"Ogri\u010d","year":"2017","journal-title":"Immunol Res"},{"key":"10.1124\/jpet.120.000179_bib23","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.120.000179_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jim.2011.09.011","article-title":"Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing","volume":"375","author":"Rispens","year":"2012","journal-title":"J Immunol Methods"},{"key":"10.1124\/jpet.120.000179_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jpba.2013.07.022","article-title":"Drug interference in immunogenicity assays depends on valency","volume":"85","author":"Rispens","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/jpet.120.000179_bib26","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.molimm.2007.10.043","article-title":"Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid","volume":"45","author":"Ryan","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1124\/jpet.120.000179_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1124\/jpet.120.000179_bib28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.120.000179_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40259-019-00394-x","article-title":"Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents","volume":"34","author":"Strand","year":"2020","journal-title":"BioDrugs"},{"key":"10.1124\/jpet.120.000179_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2010.03.012","article-title":"Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics","volume":"357","author":"Tatarewicz","year":"2010","journal-title":"J Immunol Methods"},{"key":"10.1124\/jpet.120.000179_bib31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000069457","article-title":"Natural anti-immunoglobulin autoantibodies: irrelevant by-products or immunoregulatory molecules?","volume":"115","author":"Terness","year":"1998","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1124\/jpet.120.000179_bib32","first-page":"271","article-title":"Immunosuppressive anti-immunoglobulin autoantibodies: specificity, gene structure and function in health and disease","volume":"48","author":"Terness","year":"2002","journal-title":"Cell Mol Biol"},{"key":"10.1124\/jpet.120.000179_bib33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrrheum.2017.15","article-title":"Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis","volume":"13","author":"Trouw","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1124\/jpet.120.000179_bib34","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/art.38335","article-title":"Antibodies to IgG4 hinge can be found in rheumatoid arthritis patients during all stages of disease and may exacerbate chronic antibody-mediated inflammation","volume":"66","author":"van de Stadt","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1124\/jpet.120.000179_bib35","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s10875-012-9705-0","article-title":"IgG4 production against adalimumab during long term treatment of RA patients","volume":"32","author":"van Schouwenburg","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1124\/jpet.120.000179_bib36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1124\/jpet.120.000179_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/imr.12829","article-title":"Autoantibodies and B Cells: the ABC of rheumatoid arthritis pathophysiology","volume":"294","author":"Volkov","year":"2020","journal-title":"Immunol Rev"},{"key":"10.1124\/jpet.120.000179_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.120.000179_bib39","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1158\/1078-0432.CCR-11-2203","article-title":"Bridging the gap: moving predictive and prognostic assays from research to clinical use","volume":"18","author":"Williams","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524269706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524269706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.000179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:01:08Z","timestamp":1739973668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524269706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0022356524269706"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.000179","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.000179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}